Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, SGLT2i, Topics Jan 08 | 2018JPM Day 1: J&J, Merck, Medtronic, and AbbottPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Topics Nov 21 | 2017Lilly: Thoughts on Connected Diabetes EcosystemPurchase Blast
$599
Posted in: SGLT2i, Topics Aug 11 | 2017Sotagliflozin T2DM renal Ph3 studies initiated by SanofiPurchase Blast
$599
Posted in: Insulin Delivery, Topics Jul 28 | 2017Tandem Q2 ’17 Earnings Call SummaryPurchase Blast
$599
Posted in: GLP-1RA, Topics Jun 20 | 2017LEADER Adcom Vote (17-2) in Favor of CV IndicationPurchase Blast
$599
Posted in: SGLT2i, Topics Jun 12 | 2017Invokana CANVAS/R Demonstrates 14% RRR in 3-point MACE at ADA '17Purchase Blast
$599
Posted in: Bolus Insulin, Topics May 25 | 2017Lilly’s novel uRAI lispro contains citrate and treprostinilPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i, Topics May 17 | 2017J&J Investor Event SummaryPurchase Blast
$599
Posted in: SGLT2i, Topics May 16 | 2017Invokana Boxed Warning for Lower Limb AmputationsPurchase Blast
$599
Posted in: SGLT2i, Topics May 11 | 2017Lexicon announces additional Ph3 sotagliflozin results in T1DMPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Topics May 04 | 2017Mannkind and One Drop enter collaboration for better diabetes outcomesPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i, Topics Apr 25 | 2017Lilly Q1 ’17 Earnings UpdatePurchase Blast